CRMD - CorMedix Inc.
IEX Last Trade
8.36
0.050 0.598%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:29:44 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$8.31
0.05
0.60%
Fundamental analysis
24%
Profitability
25%
Dept financing
9%
Liquidity
75%
Performance
15%
Performance
5 Days
-2.80%
1 Month
-16.28%
3 Months
7.35%
6 Months
99.28%
1 Year
122.13%
2 Year
116.64%
Key data
Stock price
$8.36
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.99 - $13.85
52 WEEK CHANGE
$113.59
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Joseph Todisco
Region: US
Website: cormedix.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cormedix.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
CorMedix Inc. focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings.
Recent news